Telavancin Hydrochloride

盐酸替拉凡星

Report date: 2026/05/11 20:01:57
NME

Base Information

Drug NameTelavancin Hydrochloride
Drug Alias Name替拉凡星Telavancina泰古霉素Telavancinumtelavancin +[11] 
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics > Glycopeptide antibiotics
Mechanisms of ActionCell wall inhibitorsPeptidoglycan inhibitors
TargetsPeptidoglycan
Therapy Area/IndicationsHospital-acquired pneumoniaComplicated Skin and Soft Tissue InfectionsBurns +[18] 
Global Approved IndicationsHospital-acquired pneumoniaComplicated Skin and Soft Tissue InfectionsPneumonia, Ventilator-Associated +[7] 
Approved Indications in ChinaHospital-acquired pneumoniaPneumonia, Ventilator-AssociatedPneumonia, Bacterial
Original Approved Country/TerritoryUnited States
Original Approved Date2009/09/11
Country/TerritoryUnited StatesIsraelEU +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesTheravance Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesTabuk Pharmaceutical Manufacturing CoTheravance IncCumberland Pharmaceuticals Inc
Inactive CompaniesTheravance Biopharma IncTheravance Biopharma Ireland UmitedThe University Of Texas MD Anderson Cancer Center +[4] 
Active IndicationsHospital-acquired pneumoniaComplicated Skin and Soft Tissue InfectionsPneumonia, Ventilator-Associated +[5] 
Inactive IndicationsBurnsUlcerKidney Failure, Chronic +[13] 

Other Information

ATC CodeJ01XA03
Related LinksWikipediaDrugBankKEGG